Patent issued for method to manufacture Immtech’s drug candidate compounds

Immtech Pharmaceuticals has announced that The United States Patent and Trademark Office issued a patent related to the manufacturing of Immtech’s drug candidate compounds.

Immtech has an exclusive, worldwide license under this patent, based on Immtech’s license agreement with the Company’s consortium of scientists. The patent, entitled “Process for the synthesis of bis-aryl diamidoxime compounds,” claims a method for making drug candidate compounds, such as Immtech’s pafuramidine maleate (DB289). The patent names scientists from both the University of North Carolina at Chapel Hill and Georgia State University as inventors.

Eric L. Sorkin, Immtech’s Chairman and Chief Executive Officer, stated, “With the issuance of this patent, Immtech now has worldwide, exclusive rights to over 150 patents including claims to compositions, methods of use, and methods of manufacturing compounds in Immtech’s large library. This patent will further augment our patent estate and commercialization efforts. We are proud of the scientific accomplishments of our partner scientists and excited about Immtech’s targeted markets.”

http://www.immtechpharma.com

Print Version
Tell-a-Friend

RELATED ARTICLES:

Moderate Use May Avert Failure of Type 2 Diabetes Drugs   Rutgers researchers identify new antibiotic target and new antibiotic mechanism   Genes affect weight loss drug effectiveness   No mental effects seen with Arimidex   Guide helps doctors manage vaccine allergies   Class of Diabetes Drugs Carries Significant Cardiovascular Risks   Medication improves alcoholics’ quality of life   Experimental drug lowers blood sugar in diabetics   Higher co-payments reduce use of antidepressants   Synthetic molecules hold promise for new family of anti-cancer drugs   Search for an HIV Vaccine Must Go On Says Expert in Light of Recent High-profile Merck Failure   When one antidepressant doesn’t work, another may